Tandem Diabetes Care (TNDM) Cash from Investing Activities Growth (3y) (2016 - 2026)
Tandem Diabetes Care (TNDM) Cash from Investing Activities Growth (3y) (2016 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 198.70 Bn | 193.10 Bn | 7.27 Bn | 17.83% |
| 2 | Stryker | 125.85 Bn | 122.37 Bn | 4.50 Bn | -6.23% |
| 3 | Medtronic | 118.44 Bn | 109.22 Bn | 6.41 Bn | -24.52% |
| 4 | Boston Scientific | 72.64 Bn | 72.10 Bn | 3.85 Bn | -32.54% |
| 5 | Edwards Lifesciences | 51.94 Bn | 47.69 Bn | 1.35 Bn | -68.12% |
| 6 | Dexcom | 34.48 Bn | 32.53 Bn | 830.00 Mn | 37.39% |
| 7 | GE HealthCare Technologies | 33.60 Bn | 31.49 Bn | 2.18 Bn | -11.04% |
| 8 | Koninklijke Philips | 26.30 Bn | 22.98 Bn | 4.55 Bn | 19.58% |
| 9 | Steris | 23.00 Bn | 22.52 Bn | 684.20 Mn | -17.67% |
| 10 | Tandem Diabetes Care | 1.56 Bn | 1.10 Bn | 144.78 Mn | -158.77% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -158.77% |
| Mar 31, 2026 | -95.07% |
| Dec 31, 2025 | -34.23% |
| Sep 30, 2025 | 51.10% |
| Jun 30, 2025 | 109.11% |
| Mar 31, 2025 | 20.91% |
| Dec 31, 2024 | 27.35% |
| Sep 30, 2024 | 20.23% |
| Jun 30, 2024 | 62.05% |
| Mar 31, 2024 | 6.03% |
| Dec 31, 2023 | 34.72% |
| Sep 30, 2023 | 29.39% |
| Jun 30, 2023 | 26.90% |
| Mar 31, 2023 | -40.94% |
| Dec 31, 2022 | 54.83% |
| Sep 30, 2022 | 13.88% |
| Jun 30, 2022 | 34.51% |
| Mar 31, 2022 | 88.33% |
| Dec 31, 2021 | -126.73% |
| Sep 30, 2021 | 5.74% |